Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis

British Journal of Haematology

Volumn 166, Issue 5, 2014, Pages 702-710

  Leiba, Merav ^a   Kedmi, Meirav ^a   Duek, Adrian ^a   Freidman, Tzachi ^a   Weiss, Mia ^a   Leiba, Ronit ^b   Nagler, Arnon ^a   Avigdor, Abraham ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Induction therapy; Multiple myeloma; Transplant eligible; Velcade cyclophosphamide dexamethasone; Velcade thalidomide dexamethasone

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; PYRAZINE DERIVATIVE; THALIDOMIDE;

HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; THALIDOMIDE;

EID: 84905990841     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12946     Document Type: Article

References (37)

1. Altman, D.G., Schulz, K.F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gotzsche, P.C. & Lang, T. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine, 134, 663-694.
2. Argyriou, A.A., Iconomou, G. & Kalofonos, H.P. (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593-1599.
3. Bensinger, W.I., Jagannath, S., Vescio, R., Camacho, E., Wolf, J., Irwin, D., Capo, G., McKinley, M., Potts, P., Vesole, D.H., Mazumder, A., Crowley, J., Becker, P., Hilger, J. & Durie, B.G. (2009) Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology, 148, 562-568.
4. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
5. Brenner, H., Gondos, A. & Pulte, D. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 111, 2521-2526.
6. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075-2085.
7. Cavo, M., Rajkumar, S.V., Palumbo, A., Moreau, P., Orlowski, R., Blade, J., Sezer, O., Ludwig, H., Dimopoulos, M.A., Attal, M., Sonneveld, P., Boccadoro, M., Anderson, K.C., Richardson, P.G., Bensinger, W., Johnsen, H.E., Kroeger, N., Gahrton, G., Bergsagel, P.L., Vesole, D.H., Einsele, H., Jagannath, S., Niesvizky, R., Durie, B.G., San Miguel, J. & Lonial, S. (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 117, 6063-6073.
8. Cavo, M., Pantani, L., Petrucci, M.T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., Nozzoli, C., Zambello, R., Masini, L., Furlan, A., Brioli, A., Derudas, D., Ballanti, S., Dessanti, M.L., De Stefano, V., Carella, A.M., Marcatti, M., Nozza, A., Ferrara, F., Callea, V., Califano, C., Pezzi, A., Baraldi, A., Grasso, M., Musto, P. & Palumbo, A. (2012) Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 120, 9-19.
9. Davies, F.E., Wu, P., Jenner, M., Srikanth, M., Saso, R. & Morgan, G.J. (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica, 92, 1149-1150.
10. Delforge, M., Blade, J., Dimopoulos, M.A., Facon, T., Kropff, M., Ludwig, H., Palumbo, A., Van Damme, P., San-Miguel, J.F. & Sonneveld, P. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet Oncology, 11, 1086-1095.
11. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
12. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420.
13. Harousseau, J.L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., Ketterer, N., Lamy, T., Voillat, L., Guilhot, F., Doyen, C., Mathiot, C. & Moreau, P. (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 27, 5720-5726.
14. Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C. & Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
15. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
16. Hideshima, T., Bergsagel, P.L., Kuehl, W.M. & Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-618.
17. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
18. Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375-4382.
19. Ludwig, H., Beksac, M., Blade, J., Boccadoro, M., Cavenagh, J., Cavo, M., Dimopoulos, M., Drach, J., Einsele, H., Facon, T., Goldschmidt, H., Harousseau, J.L., Hess, U., Ketterer, N., Kropff, M., Mendeleeva, L., Morgan, G., Palumbo, A., Plesner, T., San Miguel, J., Shpilberg, O., Sondergeld, P., Sonneveld, P. & Zweegman, S. (2010) Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist, 15, 6-25.
20. Ludwig, H., Viterbo, L., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M.B., Esteves, G., Stoppa, A.M., Robinson, D. Jr, Ricci, D., Cakana, A., Enny, C., Feng, H., van de Velde, H. & Harousseau, J.L. (2012) Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. Journal of Clinical Oncology, 31, 247-255.
21. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Treon, S.P., Munshi, N.C., Richardson, P.G., Hideshima, T. & Anderson, K.C. (2002a) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the USA, 99, 14374-14379.
22. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2002b) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525-4530.
23. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377-2380.
24. Moreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., Lepeu, G., Marit, G., Caillot, D., Escoffre, M., Lioure, B., Benboubker, L., Pegourie, B., Kolb, B., Stoppa, A.M., Fuzibet, J.G., Decaux, O., Dib, M., Berthou, C., Chaleteix, C., Sebban, C., Traulle, C., Fontan, J., Wetterwald, M., Lenain, P., Mathiot, C. & Harousseau, J.L. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 118, 5752-5758; quiz 5982.
25. Munshi, N.C., Anderson, K.C., Bergsagel, P.L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, R., Stewart, A.K., Harousseau, J.L., Dimopoulos, M., Jagannath, S., Hajek, R., Sezer, O., Kyle, R., Sonneveld, P., Cavo, M., Rajkumar, S.V., San Miguel, J., Crowley, J. & Avet-Loiseau, H. (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 117, 4696-4700.
26. Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319-4323.
27. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
28. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 23, 1337-1341.
29. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Laumann, K., Hentz, J., Pirooz, N.A., Piza, J.G., Tiedemann, R., Mikhael, J.R., Bergsagel, P.L., Leis, J.F., Fonseca, R. & Stewart, A.K. (2010) Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-3417.
30. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
31. Richardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L. & Anderson, K.C. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679-686.
32. Rosinol, L., Oriol, A., Teruel, A.I., Hernandez, D., Lopez-Jimenez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., Gonzalez, Y., Etxebeste, M.A., Diaz-Mediavilla, J., Hernandez, M.T., de Arriba, F., Gutierrez, N.C., Martin-Ramos, M.L., Cibeira, M.T., Mateos, M.V., Martinez, J., Alegre, A., Lahuerta, J.J., San Miguel, J. & Blade, J. (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 120, 1589-1596.
33. Scott, L.J. & Lyseng-Williamson, K.A. (2011) Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 71, 625-649.
34. Tricot, G., Jagannath, S., Vesole, D., Nelson, J., Tindle, S., Miller, L., Cheson, B., Crowley, J. & Barlogie, B. (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood, 85, 588-596.
35. van de Velde, H.J., Liu, X., Chen, G., Cakana, A., Deraedt, W. & Bayssas, M. (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica, 92, 1399-1406.
36. Wang, M., Giralt, S., Delasalle, K., Handy, B. & Alexanian, R. (2007) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 12, 235-239.
37. Weber, D., Rankin, K., Gavino, M., Delasalle, K. & Alexanian, R. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16-19.